A Study of LY3462817 in Participants With Rheumatoid Arthritis

J1A-MC-KDAD -

The reason for this study is to see if the study drug LY3462817 is safe and effective in participants with moderately to severely active rheumatoid arthritis (RA).

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Arthritis
What the trial is testing?
LY3462817
Could I receive a Placebo?
Yes
Enrollment Goal
98
Trial Dates
Jan 4, 2021 - Jun 29, 2022
How long will I be in the trial?
The study will last about 36 weeks and may include up to 12 visits.
Trial Phase
II

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participants must have a diagnosis of adult onset rheumatoid arthritis for at least 3 months

Participants Must Not:

  • Participants must not have had cancer within the last 5 years, except for some types of skin cancer or cervical cancer

  • Participants must not have cervical dysplasia

  • Participants must not have had certain types of infections within the last 3 months

  • Participants must not have HIV

  • Participants must not have current hepatitis virus B or C infection

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.